Your browser doesn't support javascript.
loading
Assessment of ICD eligibility in non-ischaemic cardiomyopathy patients: a position statement by the Task Force of the Dutch Society of Cardiology.
van der Lingen, Anne-Lotte C J; Verstraelen, Tom E; van Erven, Lieselot; Meeder, Joan G; Theuns, Dominic A; Vernooy, Kevin; Wilde, Arthur A M; Maass, Alexander H; Allaart, Cornelis P.
Afiliación
  • van der Lingen ACJ; Department of Cardiology, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Verstraelen TE; Department of Cardiology, Heart Centre, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
  • van Erven L; Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Meeder JG; Department of Cardiology, VieCuri Medical Centre Noord-Limburg, Venlo, The Netherlands.
  • Theuns DA; Department of Cardiology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Vernooy K; Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Wilde AAM; Department of Cardiology, Heart Centre, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
  • Maass AH; Department of Cardiology, University Medical Centre Groningen, Heart Centre, University of Groningen, Groningen, The Netherlands.
  • Allaart CP; Department of Cardiology, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. cp.allaart@amsterdamumc.nl.
Neth Heart J ; 32(5): 190-197, 2024 May.
Article en En | MEDLINE | ID: mdl-38634993
ABSTRACT
International guidelines recommend implantation of an implantable cardioverter-defibrillator (ICD) in non-ischaemic cardiomyopathy (NICM) patients with a left ventricular ejection fraction (LVEF) below 35% despite optimal medical therapy and a life expectancy of more than 1 year with good functional status. We propose refinement of these recommendations in patients with NICM, with careful consideration of additional risk parameters for both arrhythmic and non-arrhythmic death. These additional parameters include late gadolinium enhancement on cardiac magnetic resonance imaging and genetic testing for high-risk genetic variants to further assess arrhythmic risk, and age, comorbidities and sex for assessment of non-arrhythmic mortality risk. Moreover, several risk modifiers should be taken into account, such as concomitant arrhythmias that may affect LVEF (atrial fibrillation, premature ventricular beats) and resynchronisation therapy. Even though currently no valid cut-off values have been established, the proposed approach provides a more careful consideration of risks that may result in withholding ICD implantation in patients with low arrhythmic risk and substantial non-arrhythmic mortality risk.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Neth Heart J Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Neth Heart J Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos